Navigation Links
Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause
Date:6/2/2011

would be as effective as hormone therapy, without the health risks. Menerba has completed a Phase 2 trial with positive results for efficacy and has been evaluated by an independent Data and Safety Monitoring Board and passed through a standard two-round examination for safety. Menerba also has been shown in animal studies to prevent the proliferation of breast cancer and to have a beneficial effect on osteoporosis, though this has not yet been studied in humans.

About Bionovo, Inc.

Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The Company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capita
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
2. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
3. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
4. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
8. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
9. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
11. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... NORWALK, Conn. , Oct. 17, 2014 UBM ... , a leading online community and information resource for ... Parkinson disease and Alzheimer disease , with discussions ... Up to 1 million Americans have Parkinson disease , ... muscular dystrophy, or Lou Gehrig disease. Diagnosis can ...
(Date:10/17/2014)... , Oct. 17, 2014 ... the "Research and Development Prospect of China ... Based on the 2013 version, ... government policies about dialysis industry and the relevant ... research about dialysis industry segmentations. Moreover, it analyzes ...
(Date:10/17/2014)... , October 17, 2014 ... Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has announced the ... : North American Automated External Defibrillators ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The report North ... analyzes the market of devices based ...
Breaking Medicine Technology:Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2
... 20, 2011 Reportlinker.com announces that a new ... Rheumatoid Arthritis Market Forecast ... launch of novel oral drugs and reformulations of ... the seven major markets, rising from $12bn in ...
... MADISON, Wis., Sept. 20, 2011 ... the commercial launch of human iCell® Endothelial Cells ... and other life science research. Endothelial ... thus are an important factor of vascular research across ...
Cached Medicine Technology:Rheumatoid Arthritis Market Forecast 2Cellular Dynamics Announces Commercial Launch of iCell® Endothelial Cells for Vascular-Targeted Drug Discovery 2Cellular Dynamics Announces Commercial Launch of iCell® Endothelial Cells for Vascular-Targeted Drug Discovery 3Cellular Dynamics Announces Commercial Launch of iCell® Endothelial Cells for Vascular-Targeted Drug Discovery 4
(Date:10/20/2014)... MA (PRWEB) October 20, 2014 ... sponsoring a booth at the American Foundation for Suicide ... 25th. The AFSP is a not-for-profit organization that hosts ... Net proceeds from these events are used to help ... but education and personal relationships as well. , ...
(Date:10/20/2014)... Indianapolis, IN (PRWEB) October 20, 2014 ... Quick Start, a secure cloud solution that enables ... advantage of the ultimate healthcare-specific customer relationship management ... to meet the unique needs of the healthcare ... healthcare experience for providers and patients by combining ...
(Date:10/20/2014)... Principle Business Enterprises, a family owned ... top-of-the-line absorbent products. The company has recently made ... brand, Tranquility® Premium Protection absorbent products. The company ... its packaging a new look, and is currently working ... the public. , The new website, developed with Thread ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked in ... Every Body Walk! campaign by Kaiser Permanente. ... workers to be more active outside of the workplace. ... the end of September, was a friendly competition between organizations ... Participating companies gave their staff pedometers and each day, for ...
(Date:10/20/2014)... 20, 2014 Unveiled at the Sept. 18 ... Scorecard conservatively estimates member hospital ROI on membership dues at ... The Center provides $12.50 in value to member hospitals. The ... – Member Dues)/Member Dues. , “This is the first ... and we think the methodology is really sound,” said ...
Breaking Medicine News(10 mins):Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4
... new method for creating nanofibers made of proteins, developed ... (NYU-Poly), promises to greatly improve drug delivery methods for ... as well as aid in the regeneration of human ... this same development could point the way to even ...
... Center for Healthy Neighborhoods of Case Western Reserve ... groups on three of the most pressing public ... The three data briefs statistical public health ... prevalence estimates for diabetes, hypertension awareness and obesity ...
... -- Even when fast-food restaurants list calorie counts for menu ... information to make healthy meal choices, researchers report. In ... 200 food items on menu boards from 12 restaurant chains ... often, calorie counts were listed for combo meals or meals ...
... at Moffitt Cancer Center in Tampa, Fla., and colleagues ... prevent resistance to the chemotherapy drug vemurafenib, commonly used ... characterized by a diminished apoptosis (programmed cancer cell death) ... and cell survival is regulated by a family of ...
... National Jewish Health has received a grant for $950,308 ... Colorado,s San Luis Valley with educational materials for patients ... is the most common chronic illness in children and ... days. The San Luis Valley has one of the ...
... of all deaths in the United States are linked to ... inactivity. Despite these causal links, of the $2 trillion spent ... of that is devoted to addressing behavioral and social risk ... in behavioral and social sciences with a new $500,000 grant ...
Cached Medicine News:Health News:Nanofiber breakthrough holds promise for medicine and microprocessors 2Health News:First breakdown of public health data for Cleveland neighborhoods 2Health News:First breakdown of public health data for Cleveland neighborhoods 3Health News:Many Gaps in Fast-Food Nutrition Information 2Health News:Researchers find potential solution to melanoma's resistance to vemurafenib 2Health News:National Jewish Health receives grant to improve care of asthma patients in the San Luis Valley 2Health News:National Jewish Health receives grant to improve care of asthma patients in the San Luis Valley 3Health News:Training grant targets behavioral and social factors linked to health 2Health News:Training grant targets behavioral and social factors linked to health 3
... Diagnostics offers Q Fever IFA Test Kits ... and IgM human antibody responses to Coxiella ... the simultaneous semi-quantitative detection and differentiation of ... Phase II antigens. By providing the two ...
Claes Shielded Retinotomy Scissors, Vertical...
... is intended for qualitatively detecting antibodies to ... The test is indicated for testing persons ... aid in the presumptive laboratory diagnosis of ... for self-testing, and this test is not ...
... test for the detection and semi-quantitation of ... Encephalitis virus (SLE), Western Equine Encephalitis virus ... California Encephalitis/La Crosse virus (CE). Each kit ... spots of SLE, WEE, EEE, and CE ...
Medicine Products: